comparemela.com
Home
Live Updates
FDA Accepts Interim Analysis Plan for Ongoing Phase 2b Ibezapolstat Clinical Trial and Acurx Announces Presentations at ECCMID 2023 Scientific Conference : comparemela.com
FDA Accepts Interim Analysis Plan for Ongoing Phase 2b Ibezapolstat Clinical Trial and Acurx Announces Presentations at ECCMID 2023 Scientific Conference
FDA has accepted an Interim Analysis Plan for an IDMC to assess clinical outcome when 36 patients are enrolled in the Company's Ph2b clinical trial of...
Related Keywords
Copenhagen
,
Køavn
,
Denmark
,
Switzerland
,
United States
,
America
,
Kevin Garey
,
Ursula Theuretzbacher
,
Robertj Deluccia
,
European Society Of Clinical Microbiology
,
Exchange Commission On Form
,
European Congress
,
Prnewswire Acurx Pharmaceuticals Inc
,
Company Ph
,
Infectious Diseases Society Of America
,
Drug Administration
,
Exchange Commission
,
Acurx Pharmaceuticals Inc
,
Trial Oversight Committee
,
University Of Houston College Pharmacy
,
Acurx Pharmaceuticals
,
Inhibitor Program For Systemic Bacterial
,
Data Monitoring Committee
,
Society Or Healthcare Epidemiology Of America
,
Nasdaq
,
Interim Analysis Plan
,
Lead Optimization
,
Independent Data Monitoring Committee
,
Investigational New Drug Application
,
Annual European Congress
,
Clinical Microbiology
,
Infectious Disease
,
Houston College
,
Principal Investigator
,
Poster Session
,
Acurx Executive Chairman
,
Corner Presentation
,
Systemic Gram Positive
,
Executive Chairman
,
Gram Positive Selective Spectrum
,
Qualified Infectious Disease Product
,
Generating New Antibiotic Incentives Now
,
Infectious Diseases
,
European Society
,
Executive Committee
,
Clinical Practice Guidelines
,
Infectious Diseases Society
,
Healthcare Epidemiology
,
New England Journal
,
Scientific Advisory Board
,
Private Securities Litigation Reform Act
,
Nc
,
comparemela.com © 2020. All Rights Reserved.